Response to Letter Regarding Article, “Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease”

We thank Drs Jezior and Sullenberger for their interest in our article1 and agree that our observations on consistent use of proven therapies are indeed sobering. Importantly, we examined long-term consistent use, not discharge use, of evidence-based therapies, and did so specifically in patients with coronary artery disease (CAD). Of these patients, 8914 (28%) had heart failure; >61% of those patients had a documented ejection fraction (EF) <40. With regard to angiotensin-converting enzyme inhibitor (ACEI) use in CAD populations, there are …